1 week Ago
First new American College of Gastroenterology (ACG) Clinical Guideline [1] for H. pylori infection since Talicia's approval lists Talicia as an empirically prescribed first-line option Talicia's convenient all-in-one three times daily (TID) formulation offers a simplified patient experience, supporting high rates of eradication without needing prior resistance testing Talicia is the leading branded first-line therapy prescribed by U.S.
gastroenterologists [2] for H. pylori infection, which affects approximately 35% of the U.S.
adult population [3] Worldwide, around 66% of the population has H. pylori infection [4] , which is classified by the World Health Organization (WHO) as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer [5] and a major risk factor for peptic ulcer disease [6] RALEIGH, N.C.
and TEL-AVIV, Israel , Sept. 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the placement of low-dose rifabutin-triple therapy, Talicia, as an empirically-prescribed first-line option for the treatment of Helicobacter pylori ( H.
pylori ) infection in the newly published American College of Gastroenterology (ACG) Clinical Guideline: Treatment of H. pylori Infection, previously updated in 2017. "The ACG Clinical Guideline is clear that clarithromycin-based triple therapy is no longer a reliable first-line option for the treatment of H.
pylori infection, unless prior resistance testing has shown clarithromycin susceptibility. Resistance rates to both of the antibiotics contained in Talicia, amoxicillin and rifabutin, are minimal - 250 hours after the last dose. [15] The pivotal Phase 3 study with Talicia ® demonstrated 84% eradication of H.
pylori infection with Talicia ® vs. 58% in the active comparator arm (ITT analysis, p<0.0001).
[16] Talicia ® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: www.
Talicia.com . [17] Aemcolo ® (rifamycin) is indicated for the treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in adults.
For full prescribing information see: www.Aemcolo.com .
Logo - https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.
jpg SOURCE RedHill Biopharma Ltd..
